2024 Summer Intern - Health Economics and Outcomes Research (HEOR)

Ionis Pharmaceuticals, Inc.

Mar 2, 2024

Applications are closed

Internship
Full-time
Starts on Jun 10
Summer Internship
Research & Development
Science
Carlsbad
Remote

Requirements

Candidates are encouraged to apply if enrolled in a doctoral level academic program scheduled to complete after August 2024 with a focus on pharmaceutical outcomes research, health economics, or health services research. Excellent written and oral communication skills are required.
MUST be currently enrolled in a U.S. Graduate Degree Program (preferably with a focus on pharmaceutical outcomes research, health economics, or health services research) and not graduating prior to the completion of the Ionis internship in August 2024.
MUST be able to begin internship by June 11, 2024
MUST be able and willing to remain in the program through August 22, 2024.
MUST be able and willing to commit to a minimum 40-hour work week
Position can be done remotely, but some travel to Boston and Carlsbad will be required (note: travel and accommodations to Ionis offices for interns working remotely will be paid for by Ionis)
Strong interest in pharmacy outcomes research and methods is required
Excellent written and oral communications skills are required
Good interpersonal skills
Ability to work independently

Responsibilities

A key focus of the Ionis pipeline program are pediatric neuropathies, particularly rare diseases such as Alexander’s Disease (AxD), MeCP2 Duplication Syndrome, and Pelizaeus-Merzbacher Disease (PMD). The summer intern will aid in the development of the value-evidence strategy for this program by engaging in three related projects:
The development of a comprehensive literature review examining the burden of these diseases to the health system, patients and their families.
Examining the evidence gaps that exist in communicating the value of effective treatment of these conditions to US insurers and payer authorities in Canada and Europe.
Aiding in the launch of a novel project to describe the burden of these conditions by leveraging artificial intelligence in the electronic medical record.
Specific tasks performed to accomplish these projects will include:
Conduct a literature review summarizing the impact of pediatric neurodegenerative diseases, focusing on AxD, MeCP2 and PMD, but also considering analogous conditions. The review should be conducted in a manner consistent with best practices as it will be expected to result in conference presentations and peer-reviewed publications.
Coordinate with the Ionis Global Market Access team to evaluate the value-communication needs of payers and health technology authorities for pediatric neurological rare diseases and recommend evidence generation strategies to address these needs.
Assist in coordination of a natural language processing (NLP) project with an academic partner to identify patients with AxD and PMD. This will require developing a deep understanding of the partner’s proposed study protocol and methodology, making appropriate recommendations concerning the project to Ionis leaders in HEOR, Medical Affairs and Market Access, and acting as a key liaison between Ionis and the academic partner.
Through this work the project the intern will gain a deeper understanding of the following topics:
The clinical features, etiology, and epidemiological characteristics of pediatric rare neuropathies.
The impact of pediatric rare neuropathies on the quality of life of patients and their families and health care budgets.
The methods employed in the development and validation of AI methods employed for “data mining” electronic medical records.
The strategic importance of evidence generated by HEOR teams in communicating value to payers in the US, Canada, and Europe.
The internship will conclude with an in-person presentation in Carlsbad to company leadership summarizing the methods, key findings and “lessons learned” from their research.

Ionis Pharmaceuticals, Inc.

Science & Healthcare

Industry

501-1000

Employees

1989

Founded Year

Mission & Purpose

For more than 30 years, Ionis has been a leader in RNA-targeted therapy, pioneering new markets and changing standards of care. Ionis currently has four marketed medicines and a promising late-stage pipeline highlighted by cardiovascular and neurological franchises. We are guided by world-class scientists and business leaders whose great passion for innovation is equaled only by their focus and commitment to discover, develop and deliver medicines to the patients who depend on us.